Gosuranemab
Based on 1 Customer Validation
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.
For research use only. We do not sell to patients.
- Purity : 97.31%
- CAS No.: 1788032-39-2
- Molecular Weight:144.94 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
Tau
In Vitro
Gosuranemab exhibits high binding affinity to monomeric and aggregated tau and removes seeding-competent tau from AD brain lysate[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Fetal-tau/0N3R Protein, Human (His, solution, HY-P73618) can bind Gosuranemab. The EC50 for this effect is 3.367 ng/mL. -
Flow cytometric analysis of 1.5X106 SHSY5Y cells with Gosuranemab (HY-P99648, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.
Product Details
-
CAS No. 1788032-39-2
-
Accession P10636
-
Synonyms BMS-986168; IPN007; BIIB092
-
Molecular Weight 144.94 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG4 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
97.31%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
[1]. Dam T, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451-1457. [Content Brief]
[2]. Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023;3(12):1591-1601. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)